Camerini-Davalos R A, Bloodworth J M, Velasco C A, Reddi A S
Department of Medicine, New York Medical College, New York.
Clin Ther. 1994 Nov-Dec;16(6):952-61.
This study investigated the long-term effect of insulin or the combination of insulin and an oral hypoglycemic compound (glipizide) on the skeletal muscle capillary basement membrane width in insulin-requiring diabetic patients. Seventy diabetic patients were randomized to treatment with either insulin-placebo or insulin-glipizide (5 mg/d) for 3 years. Of these, only 61 patients completed the study; 27 patients received insulin-placebo and 34 patients received insulin-glipizide. Three skeletal muscle (quadriceps femoris) biopsies were performed in all patients over a 3-year period. Glycosylated hemoglobin A1 was determined every 100 +/- 20 days, including plasma glucose levels. Muscle capillary basement membrane width was quantitated by a previously described method. After approximately 16 months, glycosylated hemoglobin A1 decreased significantly in each group from its baseline (P < 0.001 insulin-glipizide group and P < 0.025 insulin-placebo), although no statistically significant difference was seen between the two groups. After 3 years this decrease was statistically significant (P < 0.001) only in the insulin-glipizide group. At baseline, no statistically significant difference was found in the muscle capillary basement membrane width between the two groups. In spite of the significant decrease in glycosylated hemoglobin A1 in both groups after 14 to 16 months, only muscle capillary basement membrane width in the insulin-glipizide group decreased significantly compared with baseline. Patients receiving insulin-placebo showed a gradual increase in the muscle capillary basement membrane width, which after 3 years was significantly higher than baseline (P < 0.02). Although the mechanisms by which the addition of glipizide to insulin treatment reduced the thickening of the muscle capillary basement membrane are not clearly understood, the current findings suggest that diabetic microangiopathy is not necessarily progressive and that prophylaxis may be attained.
本研究调查了胰岛素或胰岛素与口服降糖化合物(格列吡嗪)联合使用对需要胰岛素治疗的糖尿病患者骨骼肌毛细血管基底膜宽度的长期影响。70例糖尿病患者被随机分为胰岛素-安慰剂组或胰岛素-格列吡嗪组(5毫克/天),治疗3年。其中,只有61例患者完成了研究;27例患者接受胰岛素-安慰剂治疗,34例患者接受胰岛素-格列吡嗪治疗。在3年期间,对所有患者进行了三次骨骼肌(股四头肌)活检。每100±20天测定糖化血红蛋白A1,包括血糖水平。肌肉毛细血管基底膜宽度采用先前描述的方法进行定量。大约16个月后,每组糖化血红蛋白A1均较基线水平显著下降(胰岛素-格列吡嗪组P<0.001,胰岛素-安慰剂组P<0.025),尽管两组之间未观察到统计学上的显著差异。3年后,这种下降仅在胰岛素-格列吡嗪组具有统计学意义(P<0.001)。基线时,两组之间的肌肉毛细血管基底膜宽度未发现统计学上的显著差异。尽管两组在14至16个月后糖化血红蛋白A1均显著下降,但只有胰岛素-格列吡嗪组的肌肉毛细血管基底膜宽度较基线水平显著下降。接受胰岛素-安慰剂治疗的患者肌肉毛细血管基底膜宽度逐渐增加,3年后显著高于基线水平(P<0.02)。虽然胰岛素治疗中添加格列吡嗪减少肌肉毛细血管基底膜增厚的机制尚不清楚,但目前的研究结果表明,糖尿病微血管病变不一定是进行性的,并且可能实现预防。